SCHEDULE: Cormorant Asset Management Discloses MoonLake Stake

Cormorant Asset Management, LP and Bihua Chen have reported a beneficial ownership of 6.25% in MoonLake Immunotherapeutics' Class A ordinary shares.

Summary

• Cormorant Asset Management, LP and Bihua Chen, collectively referred to as the Reporting Persons, have filed an amendment to their Schedule 13G, reporting beneficial ownership of 4,480,433 shares of MoonLake Immunotherapeutics' Class A ordinary shares.
• This holding represents 6.25% of the class of securities outstanding.
• The filing is an amendment to a previous filing made on February 17, 2026.
• The shares are held by Cormorant Funds, for which Cormorant Asset Management, LP serves as the investment adviser.
• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership and does not contain performance data or strategic updates.

Positives

• Reporting Persons hold a significant stake of 6.25% in MoonLake Immunotherapeutics.
• The filing indicates that the securities are held in the ordinary course of business, suggesting a standard investment approach rather than a hostile takeover attempt.

Negatives

• The filing does not contain any negative financial or operational information about MoonLake Immunotherapeutics.

Risks

• The filing does not explicitly mention any risks associated with MoonLake Immunotherapeutics.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding MoonLake Immunotherapeutics' future performance.

Management Comments

• The filing includes a certification by the Reporting Persons stating that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates Cormorant Asset Management's substantial investment in the biotechnology sector, specifically in MoonLake Immunotherapeutics.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant institutional investor's stake, which can influence market perception and trading activity.

Next Steps

• The Reporting Persons will continue to hold their shares in MoonLake Immunotherapeutics in the ordinary course of business.

Key Dates

Keywords

MoonLake Immunotherapeutics, Schedule 13G, Cormorant Asset Management, Bihua Chen, beneficial ownership, Class A ordinary share, SEC filing, investment adviser